There was one blot on the landscape as incoming Novartis AG CEO Vas Narasimhan unveiled his future plans for the Swiss major, with the group's financials revealing an underwhelming performance in the US at its generics unit Sandoz Inc.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?